OOIR: Observatory of International Research

Papers

(The TQCC of Oncoimmunology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	72
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors	60
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	57
Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties	45
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors	40
Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response	40
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	39
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment	38
Nanoparticles releasing immunogenic cell death inducers upon near-infrared light exposure	38
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	38
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	37
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils	37
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint in	36
Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer	34
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 ^th immunorad conference	32
Whole stromal fibroblast signature is linked to specific chemokine and immune infiltration patterns and to improved survival in NSCLC	30
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration	29
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy	29
Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance	27
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	27
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	27
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin	26
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	26
Ferroptosis: friend or foe in cancer immunotherapy?	25
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma	25

Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma	24
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	24
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells	23
Cellular senescence enhances adaptive anticancer immunosurveillance	23
Group 2 innate lymphoid cells boost CD8 ⁺ T-cell activation in anti-tumor immune responses	22
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes	22
Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues	21
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	21
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer	21
A mitochondrial checkpoint to adaptive anticancer immunity	21
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment	21
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	21
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	20
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	20
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype	20
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy	20
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)	20
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	20
Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1	20
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	19
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	19
DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway	19
The ART of tumor immune escape	19
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	19
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome	18
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities	18
FGL2 _172-220 peptides improve the antitumor effect of HCMV-IE1mut vaccine against glioblastoma by modulating immunosuppressive cells in the tumor microenvironment	18
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses	18
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma	18
Clusterin protects mature dendritic cells from reactive oxygen species mediated cell death	17
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	17
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies	17
MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 ⁺ T cells in vivo	17
HUNK as a key regulator of tumor-associated macrophages in triple negative breast cancer	17
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma	16
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	16
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)	16
HIF2A mediates lineage transition to aggressive phenotype of cancer-associated fibroblasts in lung cancer brain metastasis	16
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutan	16
Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors	16
Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity	15
Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness	15
Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells	15
Functional and molecular characterization of PD1⁺ tumor-infiltrating lymphocytes from lung cancer patients	15
Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer	15
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	15
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	15
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	14
STING is significantly increased in high-grade glioma with high risk of recurrence	14
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	14

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer	14
Enriched circulating and tumor-resident TGF-β⁺regulatory B cells in patients with melanoma promote FOXP3⁺Tregs	14
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system	14
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	14
MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma	14
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis	14
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure	14
PDIA3 as a potential bridge between immunogenic cell death and autoreactivity	14
Association between immune-related adverse event timing and treatment outcomes	14
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	13
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes	13
Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance	13
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	13
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	13
Deep learning using bulk RNA-seq data expands cell landscape identification in tumor microenvironment	13
Trial watch: anticancer vaccination with dendritic cells	13
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	12
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma	12
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	12
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	12
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression	12
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma	12
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer	12
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors	12
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	12
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma	12
An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells	11
TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor	11
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	11
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	11
CD39 ⁺ conventional CD4 ⁺ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade	11
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer	11
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	10
Piezo1 facilitates optimal T cell activation during tumor challenge	10
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment	10
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 ⁺ T cells eradicates peritoneal metastases in mouse models	10
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6 ^th annual ImmunoRad conference	10
Tumor-infiltrating lymphocytes for melanoma immunotherapy	10
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA	10
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy	10
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis	10
Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome	10
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy	10
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors	10
Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression	10
Cell type-specific induction of ferroptosis to boost antitumor immunity	10
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade	10
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells	10
Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles	10
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro	10
Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors	10